Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentosan Polysulfate Sodium in Knee Osteoarthritis Pain
NCT06917404Phase 3Active, not recruiting
- Sponsor
- Paradigm Biopharmaceuticals
- Start
- May 2025
- Primary completion
- Jul 2027
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in osteoarthritis (OA) comparing PPS with Placebo (2 arms). Primary endpoint: Average Daily Pain Numerical Rating Scale at Day 112. Started May 2025; status: active, not recruiting.
02
Drugs
pentosan polysulfate sodium
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06917404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917404.